The effect of innate immunity on autoimmune diabetes and the expression of Toll-like receptors on pancreatic islets.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics; D007274:Injections, Intraperitoneal; D016898:Interferon-alpha / Q000096:biosynthesis; D007515:Islets of Langerhans / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008213:Lymphocyte Activation / Q000187:drug effects; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D008822:Mice, Transgenic; D010457:Peptidoglycan / Q000008:administration & dosage; D011070:Poly I-C / Q000008:administration & dosage / Q000494:pharmacology; D012330:RNA, Double-Stranded / Q000008:administration & dosage; D012367:RNA, Viral / Q000008:administration & dosage; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D013601:T-Lymphocytes / Q000276:immunology; D051196:Toll-Like Receptor 3; D051193:Toll-Like Receptors
D000276:Adjuvants, Immunologic; D016898:Interferon-alpha; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D010457:Peptidoglycan; D012330:RNA, Double-Stranded; D012367:RNA, Viral; D011956:Receptors, Cell Surface; C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3; D051193:Toll-Like Receptors; D011070:Poly I-C